Monsenso A/S develops and sells digital health solution for the treatment of depression, bipolar disorder, anxiety, schizophrenia, borderline personality disorder, and addiction and substance abuse in Denmark. The company offers Monsenso app for individuals that collects patient-reported and sensor data providing insights into symptoms, adherence, and outcomes. It also provides Monsenso solution, a software as a medical device for mental health professionals application that has data collection, direct messaging, visualization and feedback, psychoeducation and cognitive behavioral therapy, medication reminders, task reminders, consultation prepration, and platform integration that allows monitor patients remotely. In addition, the company offers Monsenso app for carers. Monsenso A/S was incorporated in 2013 and is based in Frederiksberg, Denmark.…
Monsenso (CPH: MONSO) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 9 employees.
The shares were at 0.1810 DKK on 20 November 2026, up 64.5% over 52 weeks. Its 52-week range is 0.0900 DKK to 0.5100 DKK: the price is 64.5% below the high and 101.1% above the low.
Its market capitalisation is 17.51M DKK.
Monsenso reports return on equity of -103.5%, an operating margin of -97.2% and revenue down 35.6% year over year.
Its debt exceeds its cash by 807.00K DKK, a debt-to-equity ratio of 0.26. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.